Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Monotherapy and Combinations in R/R Multiple Myeloma with t(11;14)
NCT04973605Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2021
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 2, open-label trial of sonrotoclax in multiple myeloma (MM) (2 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-limiting Toxicities at 28 days, Treatment-emergent Adverse Events and 3 more. Started Sep 2021; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04973605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973605.